Key Points

  • CEO Leon Moulder acquired 60,000 shares for a total value of approximately $1.01 million on May 18, 2026.

  • This transaction represents 13.04% of his aggregate holdings prior to the transaction.

  • The purchase is consistent with a pattern of net buying, reflecting ongoing accumulation capacity as holdings have expanded substantially over the past year.

Leon O. Molder Jr., Chief Executive Officer of Zenas BioPharma (NASDAQ:ZBIO)reported the open-market purchase of 60,000 shares at a weighted average price of $16.88 per share, according to the SEC Form 4 filing.

Transaction Summary

MetricValueShares traded60,000 Transaction value$1.0 million Post-transaction shares (direct)423,155 Post-transaction value (direct ownership)~$7.16 million

* Transaction value based on SEC Form 4 weighted average purchase price ($16.88). Post-transaction value based on May 18, 2026 closing price.

Key Questions

Exit mobile version